LQDA Stock Forecast & Price Target

Liquidia is attractive fundamentally because it is expanding a development pipeline with 10 clinical studies underway or planned to initiate within the next year, broadening the addressable market for Yutrepia across approved and new indications. The company’s strategy is commercially disciplined, using ASCENT Cohort B, LTI-403, and TRANSITION-PAH to shift patients from competing inhaled, oral, and IV/SC treprostinil therapies, while RE-WARM offers another expansion avenue in systemic sclerosis-associated Raynaud’s phenomenon. Despite meaningful legal overhangs that could affect freedom to operate, the market’s >50% correction appears to reflect severe downside scenarios, and the possibility of a larger market opportunity if it prevails on appeal supports a constructive long-term outlook.

Liquidia is facing a fundamentally weakened outlook because the court found YUTREPIA infringed two valid claims of UTHR’s ’327 patent in PH-ILD, creating a real risk of an injunction, label restriction, or royalty payments that could sharply limit commercialization. The company’s own plan to pursue an FDA supplement to remove PH-ILD may take several months, potentially up to approximately 10 months, while an appeal could take at least 12 months and potentially 18 months, leaving prolonged uncertainty over a key revenue stream. At the same time, Liquidia will likely need substantial additional capital and may face dilutive financing, even as modeled peak PAH sales of $1.1B in 2030 are offset by reduced 2026 and 2027 estimates and legal overhang.